Research output per year
Research output per year
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Research output
- 2 Article
-
Targeting NLRP3 inhibits AML progression by inducing PERK/eIF2-mediated apoptosis
Luciano, M., Sieberer, H., Krenn, P. W., Dang, H.-H., Vetter, J., Neuper, T., Amend, D., Blöchl, C., Weichenberger, C. X., Eglseer, A., Unger, M. S., Andosch, A., Steiner, P., Neureiter, D., Bauer, R., Hummer, L., Tesanovic, S., Binder, S., Elmer, D. P. & Strandt, H. & 10 others, , 2 Sept 2024, In: Cell Communication and Signaling. 22, 1, p. 424 424.Research output: Contribution to journal › Article › peer-review
Open Access -
The Class IIA Histone Deacetylase (HDAC) Inhibitor TMP269 Downregulates Ribosomal Proteins and Has Anti-Proliferative and Pro-Apoptotic Effects on AML Cells
Urwanisch, L., Unger, M. S., Sieberer, H., Dang, H.-H., Neuper, T., Regl, C., Vetter, J., Schaller, S., Winkler, S. M., Kerschbamer, E., Weichenberger, C. X., Krenn, P. W., Luciano, M., Pleyer, L., Greil, R., Huber, C. G., Aberger, F. & Horejs-Hoeck, J., 7 Feb 2023, In: Cancers. 15, 4, 1039.Research output: Contribution to journal › Article › peer-review
Open Access
Prizes
-
DSP Biomolecules in Health and Disease Symposium July 01-02, 2024
Sieberer, H. (Speaker)
1 Jul 2024 → 2 Jul 2024Activity: Talk or presentation › Oral presentation › science to science / art to art
-
The NLRP3/eIF2 axis promotes leukemic blasts survival and disease progression in acute myeloid leukemia
Unger, M. S. (Speaker), Luciano, M. (Speaker), Sieberer, H. (Speaker), Blöchl, C. (Speaker), Krenn, P. (Speaker), Vetter, J. (Speaker), Andosch, A. (Speaker), Neureiter, D. (Speaker), Strunk, D. (Speaker), Pleyer, L. (Speaker), Greil, R. (Speaker), Huber, C. (Speaker), Aberger, F. (Speaker) & Horejs-Höck, J. (Speaker)
19 Sept 2023 → 21 Sept 2023Activity: Talk or presentation › Oral presentation › science to science / art to art
-
The NLRP3 inhibitor CP-456773 reduces AML cell survival in vitro by downregulation of the FLT3 pathway
Sieberer, H. (Speaker), Luciano, M. (Speaker), Blöchl, C. (Speaker), Krenn, P. (Speaker), Eglseer, A. (Speaker), Unger, M. S. (Speaker), Vetter, J. (Speaker), Andosch, A. (Speaker), Maeding, N. (Speaker), Strunk, D. (Speaker), Greil, R. (Speaker), Huber, C. (Speaker), Aberger, F. (Speaker) & Horejs-Höck, J. (Speaker)
19 Sept 2023 → 21 Sept 2023Activity: Talk or presentation › Oral presentation › science to science / art to art
-
The NLRP3/eIF2 axis in acute myeloid leukemia
Sieberer, H. (Speaker), Unger, M. S. (Speaker), Luciano, M. (Speaker), Krenn, P. (Speaker), Blöchl, C. (Speaker), Vetter, J. (Speaker), Neuper, T. (Speaker), Bauer, R. (Speaker), Dang, H.-H. (Speaker), Greil, R. (Speaker), Huber, C. (Speaker), Aberger, F. (Speaker) & Horejs-Höck, J. (Speaker)
14 Sept 2023 → 16 Sept 2023Activity: Talk or presentation › Oral presentation › science to science / art to art
-
The NLRP3/eIF2 axis in acute myeloid leukemia
Sieberer, H. (Speaker), Unger, M. S. (Speaker), Luciano, M. (Speaker), Krenn, P. (Speaker), Blöchl, C. (Speaker), Vetter, J. (Speaker), Neuper, T. (Speaker), Bauer, R. (Speaker), Dang, H.-H. (Speaker), Greil, R. (Speaker), Huber, C. (Speaker), Aberger, F. (Speaker) & Horejs-Höck, J. (Speaker)
31 May 2023 → 2 Jun 2023Activity: Talk or presentation › Oral presentation › science to science / art to art